Becton, Dickinson and Company (NYSE:BDX) Price Target Raised to $175.00 at Piper Sandler

Key Points

• Piper Sandler raised BDX’s price target to $175 from $161 but maintained a “neutral” rating, implying approximately 0.5% downside from the cited share price. The broader analyst consensus remains “Hold,” with an average target of $186.87.
• Becton, Dickinson and Company exceeded quarterly expectations, reporting adjusted EPS of $3.23 versus $3.14 expected and revenue of $4.98 billion versus $4.89 billion expected. Revenue rose 5.4% year over year, and fiscal 2026 adjusted EPS guidance was set at $12.620–$12.720.
• BDX shares fell 0.6% to $175.93, while investors face risks from weaker year-over-year EPS and margins, insider selling, and reported product-safety recalls linked to four patient deaths.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) had its target price hoisted by investment analysts at Piper Sandler from $161.00 to $175.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a "neutral" rating on the medical instruments supplier's stock. Piper Sandler's target price indicates a potential downside of 0.53% from the company's current price.

BDX has been the subject of several other research reports. TD Cowen upped their price target on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a "hold" rating in a research report on Wednesday. Bank of America cut their price objective on shares of Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Jefferies Financial Group restated a "buy" rating and set a $210.00 target price on shares of Becton, Dickinson and Company in a report on Thursday. Evercore set a $180.00 target price on Becton, Dickinson and Company in a research report on Monday, July 6th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a report on Friday. Eight investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $186.87.

Becton, Dickinson and Company Trading Down 0.6%

NYSE:BDX traded down $1.14 during midday trading on Friday, hitting $175.93. The stock had a trading volume of 606,197 shares, compared to its average volume of 2,707,575. The stock has a 50-day moving average of $153.78 and a 200 day moving average of $162.41. The company has a market capitalization of $48.48 billion, a price-to-earnings ratio of 44.54, a PEG ratio of 12.16 and a beta of 0.19. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35. The company has a quick ratio of 0.55, a current ratio of 0.94 and a debt-to-equity ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. During the same period in the previous year, the company posted $3.68 EPS. Becton, Dickinson and Company's revenue was up 5.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts forecast that Becton, Dickinson and Company will post 12.53 EPS for the current year.

Insider Activity

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the transaction, the chief executive officer directly owned 110,163 shares in the company, valued at approximately $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company's stock, valued at $1,918,633.52. The trade was a 7.71% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 5,189 shares of company stock valued at $765,661. Insiders own 0.40% of the company's stock.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after acquiring an additional 877 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Becton, Dickinson and Company by 4.4% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier's stock valued at $122,403,000 after purchasing an additional 26,671 shares during the last quarter. Cooke & Bieler LP boosted its position in Becton, Dickinson and Company by 27.2% during the fourth quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier's stock worth $218,614,000 after purchasing an additional 240,673 shares during the period. KLP Kapitalforvaltning AS increased its holdings in shares of Becton, Dickinson and Company by 61.2% in the fourth quarter. KLP Kapitalforvaltning AS now owns 172,580 shares of the medical instruments supplier's stock valued at $33,493,000 after purchasing an additional 65,500 shares during the last quarter. Finally, Third View Private Wealth LLC bought a new position in shares of Becton, Dickinson and Company in the fourth quarter valued at about $4,992,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company News Summary

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Fiscal third-quarter results beat expectations. BD reported adjusted EPS of $3.23 versus the $3.14 consensus and revenue of approximately $5.0 billion versus estimates of $4.89 billion. Revenue increased 5.4% year over year, supported by growth across its Medical Essentials and Interventional segments. BD Reports Third Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD raised its fiscal 2026 outlook. The company now expects adjusted EPS of $12.620 to $12.720, above the $12.56 analyst consensus, and expects revenue growth toward the high end of its prior range. Year-to-date operating cash flow rose 33.3% to $2.1 billion, while free cash flow increased 44.6% to $1.7 billion. Becton Dickinson Signals Strong Growth Momentum By Raising Profit Outlook
• Neutral Sentiment: Analyst support remains cautious. Wells Fargo raised its price target from $161 to $170 but maintained an “equal weight” rating. The new target still implies roughly 3% downside from the referenced share price, limiting the positive impact of the earnings beat. Wells Fargo BDX Price Target Update
• Negative Sentiment: Profitability showed signs of pressure. Although revenue and adjusted EPS exceeded estimates, quarterly EPS declined from $3.68 a year earlier, while gross and operating margins weakened. Investors may view those trends as a risk to the durability of BD’s earnings growth.
• Negative Sentiment: Product-safety concerns add risk. BD reportedly recalled vascular-access-system needles following four patient deaths, creating potential regulatory, legal and reputational risks. BD Recalls Vascular Access System Needles

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source